Clinical Customer Growth
In 2024, Alpha Teknova supported 48 clinical customers, up from 34 at the end of 2023, a 41% annual increase.
Revenue Growth in Key Segments
Revenue from sales to cell and gene therapy-related customers grew by 27% in 2024. The custom biopharma segment grew about 40% compared to 2023.
Operational Efficiency
Operating expenses were reduced by $8.1 million in 2024 compared to 2023, excluding nonrecurring charges.
Improved Cash Outflow
Total cash outflow was $13.5 million, better than the initial guidance of $18 million, and significantly improved from $26.7 million in 2023.
New Product Launches
Three new offerings were launched in 2024: Build Tech, Express Tech, and RUO Plus.